Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-04
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Oral mSWI/SNF Degrader and Resistance in Prostate Cancer Mod

    2026-07-28

    Development of an Orally Bioavailable mSWI/SNF ATPase PROTAC and Overcoming Resistance in Prostate Cancer

    Study Background and Research Question

    Epigenetic regulation via the mammalian switch/sucrose nonfermentable (mSWI/SNF) chromatin remodeling complex has emerged as a critical therapeutic target in enhancer-driven cancers. The mSWI/SNF complex, comprising multiple subunits—including the ATPases SMARCA2 and SMARCA4—regulates gene expression by modulating chromatin accessibility. While small-molecule inhibitors and degraders targeting mSWI/SNF ATPases have shown promise in preclinical models, the practicality and efficacy of these agents are often limited by poor oral bioavailability and the emergence of resistance. The reference study set out to address two central questions: Can a dual mSWI/SNF ATPase degrader be developed with favorable oral pharmacokinetics and antitumor activity? And what are the mechanisms by which prostate cancer cells acquire resistance to such targeted therapies?

    Key Innovation from the Reference Study

    The authors present AU-24118, an orally bioavailable proteolysis-targeting chimera (PROTAC) designed to degrade both SMARCA2 and SMARCA4 ATPases, as well as PBRM1, a component of the polybromo-BAF (pBAF) complex. This represents a significant advance over previous intravenous-only PROTACs. AU-24118 demonstrated robust tumor regression in castration-resistant prostate cancer (CRPC) models, and its efficacy was further enhanced in combination with the androgen receptor antagonist enzalutamide. Importantly, the study also probes mechanisms of acquired resistance, revealing both genetic (SMARCA4 bromodomain mutations) and transporter-mediated (ABCB1/P-glycoprotein overexpression) mechanisms, with the latter conferring broad resistance to multiple PROTAC degraders.

    Methods and Experimental Design Insights

    The research team employed a multi-pronged approach:

    • Compound Development: AU-24118 was synthesized as a dual-target PROTAC capable of binding SMARCA2/4 and recruiting E3 ubiquitin ligases for proteasomal degradation.
    • Pharmacokinetics and Safety: The oral bioavailability, systemic exposure, and toxicity of AU-24118 were evaluated in both mice and rats, with favorable absorption and safety profiles reported.
    • In Vivo Efficacy: Efficacy was assessed in mouse xenograft models of CRPC, both as monotherapy and in combination with enzalutamide, a standard-of-care AR antagonist.
    • Resistance Mechanism Elucidation: Prostate cancer cell lines were subjected to prolonged high-dose exposure to mSWI/SNF degraders. Resistant clones were characterized by genomic sequencing and transcriptomic analysis to identify recurrent alterations.
    • Reversal of Resistance: Functional assays tested the effect of P-glycoprotein (P-gp/ABCB1) inhibition on resensitizing resistant cells to PROTAC degraders.

    Core Findings and Why They Matter

    The reference study's core discoveries have broad implications for targeted cancer therapy:

    • Oral mSWI/SNF Degrader Efficacy: AU-24118 induced significant tumor regression in preclinical CRPC models, with enhanced effect when combined with enzalutamide, supporting its translational potential for oral administration in clinical settings (reference study).
    • Pharmacokinetic and Safety Profiles: Oral dosing achieved therapeutically relevant plasma concentrations without notable toxicity, an essential criterion for clinical translation.
    • Resistance Mechanisms: Two distinct mechanisms emerged from long-term drug exposure:
      • SMARCA4 Bromodomain Mutations: These mutations conferred resistance specifically to mSWI/SNF degraders, illustrating a classical target modification scenario.
      • ABCB1/P-gp Overexpression: Upregulation of the ABCB1 transporter led to broad multidrug resistance (MDR), reducing efficacy not only of mSWI/SNF degraders but also of other PROTACs targeting proteins such as BRD4 and AR.
    • Reversal by P-gp Inhibition: The study demonstrates that the P-gp inhibitor Zosuquidar (LY335979) can restore sensitivity to multiple PROTAC degraders in resistant cell lines, directly implicating P-glycoprotein efflux pump inhibition as a strategy to overcome acquired MDR in this context.

    These findings underscore the dual challenge and opportunity: as next-generation, orally available degraders reach preclinical maturity, the need to anticipate and overcome transporter-mediated resistance becomes paramount for sustained clinical benefit.

    Comparison with Existing Internal Articles

    Insights from the reference study complement and extend the mechanistic paradigm described in several internal resources. For example, the article "Zosuquidar (LY335979) 3HCl: Selective P-gp Inhibition in MDR Oncology" details how Zosuquidar achieves restoration of chemotherapeutic sensitivity in various MDR cancer models by targeting P-gp-mediated drug efflux. Similarly, "Zosuquidar (LY335979) for Reversing Multidrug Resistance in Cancer" provides practical guidance for integrating Zosuquidar into in vitro and in vivo workflows, with emphasis on its selectivity and minimal toxicity profile.

    What distinguishes the reference paper is its documentation of ABCB1/P-gp upregulation as a resistance mechanism not just against conventional chemotherapeutics but also against novel PROTAC degraders—expanding the clinical relevance of P-gp inhibitors like Zosuquidar to the emergent field of targeted protein degradation. This mechanistic link aligns with guidance from "Precision Targeting of Multidrug Resistance: Zosuquidar", which discusses the translational impact of P-gp inhibition in both hematologic and solid tumor settings, including acute myeloid leukemia (AML) and non-Hodgkin’s lymphoma chemotherapy enhancement strategies.

    Limitations and Transferability

    While the study sets a robust preclinical foundation, several limitations should be noted. First, the resistance mechanisms were identified primarily in cell line and murine models; additional validation in patient-derived xenografts or clinical samples is necessary to confirm their clinical prevalence. Second, the focus on prostate cancer, though appropriate for the study, means further research is needed to generalize these findings to other tumor types reliant on mSWI/SNF activity or treated with PROTACs. Finally, while Zosuquidar (LY335979) effectively resensitized resistant cells in vitro, its translation to combination regimens with oral degraders in clinical oncology will require careful pharmacokinetic and toxicity profiling, as well as consideration of potential drug-drug interactions.

    Protocol Parameters

    • PROTAC treatment duration: Chronic high-dose exposure (weeks) is necessary for modeling acquired resistance in cell lines.
    • P-gp inhibitor application: Zosuquidar (LY335979) at low micromolar concentrations (e.g., 0.1–1 μM) was shown to fully restore sensitivity to PROTACs in resistant models, as supported by product information and preclinical literature.
    • Combination regimens: Co-administration with standard-of-care agents (e.g., enzalutamide) can be used to model clinical treatment synergies.
    • In vivo considerations: Zosuquidar enhances antitumor activity without markedly altering chemotherapeutic pharmacokinetics in murine models, but solutions should be freshly prepared due to DMSO solubility and stability limitations.

    Research Support Resources

    For researchers designing workflows to address multidrug resistance (MDR) in cancer or to model acquired resistance in PROTAC-based drug development, Zosuquidar (LY335979) 3HCl (SKU A3956) is a validated, potent, and selective P-glycoprotein inhibitor. Its use has been extensively characterized in preclinical and translational studies for reversing P-gp-mediated drug resistance and supporting advanced screening protocols. For protocol optimization and troubleshooting, the internal articles referenced above offer detailed mechanistic and workflow guidance. Zosuquidar is supplied by APExBIO as a trihydrochloride salt for research use only and should be handled with attention to solubility and storage recommendations to ensure experimental fidelity.